Catalent, Inc. (NYSE:CTLT) Shares Sold by Sand Grove Capital Management LLP

Sand Grove Capital Management LLP trimmed its position in Catalent, Inc. (NYSE:CTLT - Free Report) by 11.8% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 429,848 shares of the company's stock after selling 57,346 shares during the period. Catalent comprises approximately 10.2% of Sand Grove Capital Management LLP's holdings, making the stock its 3rd largest holding. Sand Grove Capital Management LLP owned about 0.24% of Catalent worth $26,036,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brooklyn Investment Group acquired a new stake in shares of Catalent in the third quarter valued at approximately $31,000. Sentry Investment Management LLC bought a new stake in shares of Catalent during the 3rd quarter valued at approximately $53,000. Longfellow Investment Management Co. LLC raised its position in Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock valued at $55,000 after purchasing an additional 305 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock worth $58,000 after acquiring an additional 212 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. grew its holdings in Catalent by 57.5% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company's stock worth $72,000 after acquiring an additional 431 shares during the period.

Insider Buying and Selling

In other news, Director Michelle R. Ryan sold 2,800 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,114 shares of company stock worth $305,931. 0.31% of the stock is owned by insiders.

Catalent Stock Performance

Shares of Catalent stock traded up $0.18 on Thursday, reaching $62.02. 2,185,613 shares of the company were exchanged, compared to its average volume of 2,040,426. Catalent, Inc. has a 1-year low of $36.74 and a 1-year high of $62.20. The stock's 50 day moving average price is $60.00 and its 200-day moving average price is $58.62. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51.

Catalent (NYSE:CTLT - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm's revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.10) EPS. Research analysts anticipate that Catalent, Inc. will post 0.84 EPS for the current year.

Wall Street Analyst Weigh In

CTLT has been the topic of several recent research reports. William Blair reaffirmed a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. Robert W. Baird reiterated a "neutral" rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Baird R W cut Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Finally, StockNews.com upgraded shares of Catalent from a "sell" rating to a "hold" rating in a research report on Monday. Eight investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $63.40.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.